Cytogen (217330.KQ) Osake Kurssi

CytoGen, Inc. is a holding company which engages in the researche and development of cancer treatment solutions. The company is headquartered in Seoul, Seoul and currently employs 43 full-time employees. The company went IPO on 2018-11-22. The liquid biopsy application services include biomarker discovery and verification services, as well as liquid biopsy-based precision medical services which is the commercialization of companion diagnostics (CDx) development, among others. The biomarker discovery and verification services include circulating tumor cell (CTC)-based biomarker discovery and validation, gene mutation and transcript expression analysis, and drug testing and analysis services, among others. The liquid biopsy-based precision healthcare services include companion diagnosis, re-selection of therapeutic drugs, examination and treatment effectiveness monitoring, and recurrence prediction services, among others. In addition, the Company develops and sells platforms and kits for liquid biopsy. The firm distributes its products within the domestic market and to overseas markets.